ArticleBioorganic & medicinal chemistry letters2010
Dendrimer-based tumor cell targeting of fibroblast growth factor-1.
Article in Bioorganic & medicinal chemistry letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Applying dendrimer nanoprobes to the diagnosis and evaluation of kidney fibrosis.Nanomedicine (London, England) · 2026Review
- Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma.Materials today. Bio · 2024Article
- Biocompatible Macroion/Growth Factor Assemblies for Medical Applications.Biomolecules · 2023Review
- Novel G-CSF conjugated anionic globular dendrimer: Preparation and biological activity assessment.Pharmacology research & perspectives · 2021Article
- Fibroblast Growth Factor Signalling in the Diseased Nervous System.Molecular neurobiology · 2021Review
- Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors.ACS omega · 2017Article
- Comparison of Different Crosslinking Methods for Preparation of Docetaxel-loaded Albumin Nanoparticles.Iranian journal of pharmaceutical research : IJPR · 2015Article
- Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Applied biochemistry and biotechnology · 2011Review
- A multivalent probe for AI-2 quorum-sensing receptors.Journal of the American Chemical Society · 2011Article
- Structurally Diverse Nitric Oxide-Releasing Poly(propylene Imine) Dendrimers.Chemistry of materials : a publication of the American Chemical Society · 2011Article
- Biomarker identification with ligand-targeted nucleoprotein assemblies.Nanomedicine (London, England) · 2011Article
- Imaging and drug delivery using theranostic nanoparticles.Advanced drug delivery reviews · 2010Review
- Cell-mediated Delivery and Targeted Erosion of Vascular Endothelial Growth Factor-Crosslinked Hydrogels.Macromolecular rapid communications · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast Growth Factor Receptor (FGFR) is overexpressed in a wide variety of tumors, and therefore is an attractive target for drug delivery. Recombinant FGF-1 was purified and attached to a fifth-generation (G5) polyamidoamine dendrimer. The specific binding and internalization of this conjugate labeled with FITC was demonstrated by flow cytometry as well as by confocal microscopic analysis in cell lines expressing FGFR. The binding and uptake of FGF-conjugated dendrimers was completely blocked by excess nonconjugated FGF-1. Confocal microscopic analysis showed cytosolic as well as nuclear localization. Multivalent G5-FGF nanoparticles may serve as a platform for cytosolic as well as nuclear drug delivery in tumor cells, and as an FGF delivery agent for angiogenesis and wound healing. Our study shows for the first time the applicability of a dendrimer nanodevice for tumor cell targeting through FGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.